Medtronic plc (NYSE:MDT - Get Free Report)'s stock price traded down 0.1% during trading on Tuesday . The company traded as low as $87.81 and last traded at $88.18. 801,575 shares changed hands during trading, a decline of 87% from the average session volume of 6,170,045 shares. The stock had previously closed at $88.27.
MDT has been the subject of several research reports. Truist Financial upped their price target on shares of Medtronic from $90.00 to $93.00 and gave the company a "hold" rating in a research report on Monday, October 14th. Daiwa America raised Medtronic to a "strong-buy" rating in a research report on Friday, August 23rd. Stifel Nicolaus increased their price target on Medtronic from $85.00 to $87.00 and gave the company a "hold" rating in a research note on Wednesday, August 21st. Needham & Company LLC reissued a "hold" rating on shares of Medtronic in a report on Friday, October 25th. Finally, Barclays upped their target price on shares of Medtronic from $104.00 to $105.00 and gave the stock an "overweight" rating in a report on Thursday, August 22nd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $95.36.
Get Our Latest Analysis on Medtronic
The stock has a market capitalization of $113.18 billion, a price-to-earnings ratio of 29.78, a PEG ratio of 2.51 and a beta of 0.84. The firm has a 50-day moving average of $89.67 and a 200 day moving average of $84.57. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.13 and a quick ratio of 1.61.
Medtronic (NYSE:MDT - Get Free Report) last posted its earnings results on Tuesday, August 20th. The medical technology company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.20 by $0.03. The company had revenue of $7.97 billion for the quarter, compared to the consensus estimate of $7.90 billion. Medtronic had a return on equity of 13.68% and a net margin of 12.06%. The firm's revenue for the quarter was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.20 earnings per share. As a group, sell-side analysts forecast that Medtronic plc will post 5.44 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Friday, October 11th. Shareholders of record on Friday, September 27th were issued a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 3.17%. The ex-dividend date of this dividend was Friday, September 27th. Medtronic's dividend payout ratio is presently 94.59%.
Hedge funds have recently added to or reduced their stakes in the stock. Fortitude Family Office LLC acquired a new position in Medtronic in the 3rd quarter valued at approximately $27,000. Highline Wealth Partners LLC acquired a new stake in Medtronic during the third quarter worth approximately $27,000. Darwin Wealth Management LLC acquired a new position in Medtronic in the third quarter valued at approximately $27,000. Lynx Investment Advisory bought a new position in shares of Medtronic during the 2nd quarter worth approximately $28,000. Finally, Gleason Group Inc. bought a new stake in shares of Medtronic in the 2nd quarter valued at $42,000. Institutional investors and hedge funds own 82.06% of the company's stock.
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Medtronic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.
While Medtronic currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.